
Cuts will hit the poorest, most vulnerable and disabled in Scotland
The Coalition’s welfare cuts will hit the “poorest, most vulnerable and those with disabilities” in Scotland, a new report out today reveals.

The Coalition’s welfare cuts will hit the “poorest, most vulnerable and those with disabilities” in Scotland, a new report out today reveals.

It has been described as the Coalition’s Charge of the Light Brigade – but now it seems the cavalry are having second thoughts, the cavalry being GPs.

With forthcoming cuts to research and possible restrictions on the entry of foreign students today’s world university Rankings are very timely.

Scottish Labour have dubbed a “disgrace” education secretary Michael Russell’s announcement on class sizes for primary school children in year one.

90 per cent of the public think that “it was important for the Government to invest in UK universities”. 4-in-5 believe that investment should rise or stay the same.

Ed Balls took time out from holding Michael Gove to account at the weekend to turn his ammo on Gove’s deputy Sarah Teather, who has thus far escaped censure for the schools cuts – and who it now emerges lobbied her boss to give preferential treatment to schools in her Brent Central constituency and spare them the Building Schools for the Future axe.

In less than a decade, the United Kingdom has slumped from third to 15th position in the number of students graduating, it emerged today.

Leaks coming from inside former BP boss, Lord Browne’s review of higher education funding today suggest that will stay true to his big business background and suggest the Government raises the cap on tuition fees to £7,000 and subject universities and students to the perils of a market.

In an address to the Fabian Society this morning, Ed Balls unveiled new research which attacks Michael Gove’s academies programme for being elitist.

Once again NICE, the NHS rationing ‘quango’, has been in the news with its decision not to recommend the Roche manufactured drug Avastin for metastatic bowel cancer. The roots of the decision and the history between Roche and NICE go back a bit further though.